Healthcare Industry News: Sienna Biopharmaceuticals
News Release - March 24, 2017
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial OfficerWESTLAKE VILLAGE, Calif., March 24, 2017 -- (Healthcare Sales & Marketing Network) -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as Chief Financial Officer, effective March 24.
Peterson, who brings more than two decades of global financial experience, will succeed John Smither, who is retiring at the end of April but will continue to serve Sienna in an advisory capacity. Peterson joins Sienna from Novan, Inc., where he served as Chief Financial Officer for the pharmaceutical dermatology company. Previously, he was the Chief Financial Officer and Treasurer of Medicis Pharmaceutical Corporation until the company's acquisition in 2012 by Valeant Pharmaceuticals International, Inc., for $2.6 billion.
"We are pleased to welcome Ric to Sienna and look forward to his contributions as we advance our robust and diversified pipeline of topical biotech products," said Frederick C. Beddingfield III, M.D., Ph.D., Sienna's President and Chief Executive Officer. "Ric is an accomplished financial leader with a proven track record of creating value for medical dermatology and aesthetic companies that develop and market industry-leading products."
During Peterson's tenure at Medicis, the company achieved significant growth in revenue and profitability with a portfolio of top-selling medical and aesthetic products including SOLODYN® for acne and Restylane® and Dysport® for the treatment of facial wrinkles. Prior to Medicis, Peterson was a Senior Financial Auditor with PricewaterhouseCoopers. He holds a Bachelor of Science in accountancy from Arizona State University.
"I am delighted to join the Sienna team at such an exciting time for the company," Peterson said. "Sienna is poised, with innovative topical platform technologies, to address significant unmet needs and fundamentally change the treatment of dermal inflammation and aesthetic skin conditions, and I am eager to contribute to the company's success."
Sienna is developing first-in-class late-stage clinical candidates to create targeted safe and effective topical therapies that treat conditions such as psoriasis, atopic dermatitis, pruritus, acne vulgaris and unwanted light-pigmented hair with limited systemic exposure.
"I would like to recognize and thank John Smither, who has worked tirelessly to help establish Sienna and expand our portfolio," Dr. Beddingfield said. "John has been instrumental in securing financing and building a stellar finance team that sets Sienna up for success as we move forward. We are pleased that we will continue to benefit from his counsel."
About Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics. The company's investors include: ARCH Venture Partners; Partner Fund Management; Altitude Life Science Ventures; Venvest Capital; Two River; and several prominent medical dermatology and aesthetics industry luminaries. Find more information at www.siennabio.com.
SOLODYN® is a registered trademark of Valeant Pharmaceuticals International, Inc.; Restylane® and Dysport® are registered trademarks of Galderma.
Source: Sienna Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.